Fibroblast growth factors (FGFs) are secreted protei n ligands that act in a paracrine or endocrine fashion to carry out their pleiotropic functions in development, tissu e homeostasis and metabolism. The mammalian FGF family comprises 18 ligands, which are grouped into five paracrine-acting subfamilies and one e ndocrine-acting subfamily on the basis of sequence homology and phylogenetic and structural analysis 1,2 (FIG. 1a) . FGF ligands signal through cell surface FGF receptor (FGFR) Tyr kinases, which are encoded by four distinct genes in mammals (FGFR1-FGFR4) 3 (FIG. 1b) .
which brings the intracellular receptor kinase domains in the correct proximity and orientation to each other such that transphosphorylation, and hence activation, of the kinases can occur 5, 6 . The activated receptor kinases, in turn, phosphorylate and activate their intra cellular substrates, chief among which are FGFR substrate 2α (FRS2α) and phospholipase Cγ1 (PLCγ1) 7, 8 (FIG . 2) . Activated FRS2α initiates downstream signalling through the RAS-MAPK pathway or the PI3K-AKT pathway, whereas the activation of PLCγ1 leads to release of calcium ions from intracellular stores and activation of protein kinase C (PKC) [7] [8] [9] [10] [11] (FIG. 2) .
Although the biological outcome of activation of these pathways by FGFs varies depending on the cellular context, the RAS-MAPK pathway mostly generates a mitogenic cell response, the PI3K-AKT pathway promotes cell survival and the PLCγ1 pathway is thought to have a role in mediating cell motility [7] [8] [9] [10] [11] (FIG. 2) .
A common characteristic of FGFs is that they interact with heparan sulphate glycosaminoglycan chains of heparan sulphate proteoglycans 12 , which are abundantly present both at the cell surface and in the pericellular and extracellular matrix 13 (FIG. 1b) . Paracrine FGFs exhibit a much higher affinity for heparan sulphate than endocrine FGFs 12 , and therefore, paracrine FGFs become immobilized in the pericellular and extracellular matrix near the site of their secretion and can only act on cells within the same organ. By contrast, owing to their poor affinity for heparan sulphate 12, 14 , endocrine FGFs can freely diffuse away from the cells secreting them and enter the blood circulation to reach their target cells in distant organs. Whereas paracrine FGFs require heparan sulphate as a cofactor to activate FGFR 15, 16 ( FIG. 1c) , endocrine FGFs rely on Klotho co-receptors to do so [17] [18] [19] [20] [21] [22] [23] (FIG. 1b,d ) (see below). Paracrine FGFs have essential roles in virtually every step during embryonic development, including the induction and patterning of germ cell layers, the formation of body axes, the induction of organogenesis and morphogenes is and the patterning of tissues 1, 9, 10, 24 . These ligands also fulfil crucial functions in a number of homeostatic processes in the adult organism, most notably in the repair and remodelling of tissues [25] [26] [27] [28] . Endocrine FGFs regulate multiple metabolic processes, including phosphate, glucose and lipid metabolism [29] [30] [31] [32] . The broad range of FGF functions is reflected in the diversity of disorders caused by dysregulated FGF signalling, including developmental syndromes, metabolic disorders and cancer FGF1  FGF2  FGF3  FGF7  FGF10  FGF22  FGF4  FGF5  FGF6  FGF8  FGF17  FGF18  FGF9  FGF16  FGF20  FGF19  FGF21 , and FGF19, an endocrine FGF (PDB ID: 2P23) 14 are shown. The conserved globular core domain consists of 12 β-strands in FGF2 and 11 β-strands in FGF19. Residues from the loop connecting β-strand 1 and β-strand 2 and from the region between β-strand 10 and β-strand 12 comprise the heparan sulphate-binding site (shown in blue). The conformation of the FGF19 heparan sulphate-binding site differs from the conserved conformation of the heparan sulphate-binding site in paracrine FGFs, which are represented here by FGF2. b | The domain architecture of a prototypical FGF receptor and Klotho co-receptor are shown. Alternative splicing in the D3 domain of FGFR1, FGFR2 and FGFR3 generates FGFRb and FGFRc isoforms with distinct ligand-binding specificity 37, 39, [66] [67] [68] [69] [70] [71] [72] . FGFRs interact with cell surface heparan sulphate via their D2 domain. Heparan sulphate is the obligatory cofactor for paracrine FGF signalling. A schematic of an heparan sulphate proteoglycan and the crystal structure of an heparan sulphate octasaccharide (PDB ID: 1FQ9) 4 are shown. c | The crystal structure of the 2:2:2 ternary complex of FGF2, FGFR1c and heparan sulphate (PDB ID: 1FQ9) 4 as well as a schematic of the paracrine FGF signal transduction unit based on this structure are shown. In the ternary complex, each FGF ligand interacts extensively with one receptor through the primary ligand-binding site comprising D2, D3 and the D2-D3 linker of the receptor. Each ligand also binds to the adjoining receptor in the complex through a secondary ligand-binding site on the D2 domain, which is adjacent to the site mediating the receptor-receptor interaction. Heparan sulphate promotes the formation of the 2:2 paracrine FGF-FGFR complex through concomitant interaction with both ligand and receptor. d | A schematic of two working models for the endocrine FGF-FGFR-Klotho co-receptor signal transduction unit is shown. A recent study on the ternary complex formation between FGF21, FGFR1c and β-Klotho supports the 1 
Morphogenesis
Process of cell movement during embryonic development that controls the size, shape and patterning of tissues and organs.
β-trefoil
Portion of a protein that consists of 12 β-strands arranged into 3 similar sets of 4-stranded β-sheets.
The structural information gained about the FGF signalling system in recent years has begun to illuminate the complexity of its molecular control, which is in place to fine-tune this system to enable it to produce specific signalling outputs in diverse biological contexts. This Review discusses, through the lens of structural biology, the molecular mechanisms by which the FGF signalling system is regulated extracellularly at the level of the ligand, the receptor, the heparan sulphate cofacto r and the Klotho co-receptor. The specific mechanisms covered include autoinhibition of the ligand by homodimerization, ligand inactivation by site-specific proteolytic cleavage, modulation of the receptor-binding affinity of the ligand by alternative splicing and differences in ligand-induced receptor dimerization between different ligand-receptor pairs. We also discuss the mechanism by which Klotho co-receptors convert FGFRs into specific receptors for endocrine FGFs.
Regulation of FGF ligand activity
FGFs share a core homology domain of about 120 amino acids, which folds into a globular β-trefoil. Paracrine FGFs have a regular β-trefoil domain that is composed of 12 β-strands (β1-β12) 2 , whereas endocrine FGFs have an atypical β-trefoil due to the lack of the β11 strand 14 . The conserved core domain is flanked by highly divergent amino-terminal and carboxy-terminal sequences, which have a key role in conferring distinct functional properties on FGFs [35] [36] [37] [38] [39] . FGF activity is regulated by multiple mechanisms, including heparan sulphate binding, N-terminal alternative splicing, homodimerization and site-specific proteolytic cleavage of the FGF ligand. Among these, the interaction of FGFs with heparan sulphate is the most important in determining the biological activity of the ligand. It not only defines the mode of action of FGFs, that is, whether an FGF acts in a paracrine or endocrine fashion, but also contributes to the Binding of fibroblast growth factor (FGF) to the FGF receptor (FGFR) induces FGFR dimerization, which juxtaposes the intracellular Tyr kinase domains of the receptors so that kinase activation by transphosphorylation can occur 5, 6 . Activated FGFR kinase in turn activates its intracellular substrates by phosphorylation, setting in motion distinct but potentially interactive signalling pathways that generate diverse cellular responses [9] [10] [11] . Major substrates of FGFR kinase are FGFR substrate 2α (FRS2α), which is constitutively associated with the receptor kinase, and phospholipase Cγ1 (PLCγ1) 7, 8 . Activated FRS2α binds the adaptor protein growth factor receptor-bound 2 (GRB2) 113 . GRB2 then recruits either the guanine nucleotide exchange factor son of sevenless (SOS) (a) or the adaptor protein GRB2-associated binding protein 1 (GAB1) (b) to the signalling complex. Recruited SOS activates RAS GTPase, which initiates activation of the MAPK cascade 113 (a), whereas recruited GAB1 leads to PI3K-mediated activation of AKT kinase (also known as protein kinase B) 114 (b). Activated MAPK translocates from the cytoplasm to the nucleus, where it phosphorylates and hence activates immediate early gene transcription factors, such as FOS to induce transcription of specific genes (a). The outcome of this pathway is primarily cell proliferation but can also lead to cell differentiation, cell migration or another cellular response [9] [10] [11] . Activated AKT kinase, on the other hand, inactivates pro-apoptotic effectors such as the BCL-2 antagonist of cell death (BAD) and forkhead box class O (FOXO) transcription factors, thereby promoting cell survival 115,116 (b) . Recruitment and phosphorylation of PLCγ1 by FGFR kinase initiates a distinct signalling pathway that is thought to have roles in cell migration and cell differentiation and that can influence the RAS-MAPK and PI3K-AKT pathways (c). Activated PLCγ1 catalyses the hydrolysis of the membrane phospholipid phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)(P 2 ) into diacylglycerol (DAG) and i nositol-1,4,5,-trisphosphate (IP 3 ) 8 . DAG activates protein kinase C (PKC), which in turn activates its substrates by phosphorylation, including the myristoylated Ala-rich C kinase substrate (MARCKS), a regulator of cell motility 117 . IP 3 stimulates the release of calcium ions from intracellular stores, and this triggers the activation of calcium-dependent proteins such as the phosphatase calcineurin. Activated calcineurin induces nuclear translocation of the transcription factor nuclear factor of activated T cells (NFAT), which stimulates the expression of proteins essential for cell motility 118 . BAX, BCL-2-associated X protein; MAPKK, MAPK kinase; PDK, phosphoinositide-dependent protein kinase.
Epimerization
Process by which an epimer of a molecule is converted into its stereoisomeric counterpart.
Submandibular gland
Gland located under the mandible bone that secretes saliva into the mouth.
Elbow knee synostosis
(Eks). Mouse skeletal phenotype characterized by bone fusion at elbow and knee joints.
Lacrimal gland
Gland of the eye that produces tear fluid to keep the eye lubricated.
distinct biological activities of paracrine ligands within the same subfamily.
Interaction of FGF ligand with heparan sulphate. The interaction between heparan sulphate and paracrine FGFs serves, among other roles, to sequester ligand near the site of action, provide a reservoir for ligand storage, enhance ligand stability and limit the radius of ligand signalling. In this subsection, we discuss the emerging concept that differences in heparan sulphate-binding affinity among paracrine FGFs, including ligands of the same subfamily, underlie the formation of different, ligand-specific gradients in the extracellular matrix, which produce distinct biological responses.
Heparan sulphate is a linear glycan composed of repeating disaccharide units of N-substituted glucosamine and glucuronic acid 13, 40 . N-sulphated domains of 5-10 disaccharide units in length that harbour variou s modifications alternate along the glycan chain with N-acetylated regions that are mostly unmodified 13, 40 . Modifications at N-sulphated domains include C5 epimerization of glucuronic acid to iduronic acid, 2-O-sulphation of glucuronic or iduronic acid and 3-O-and 6-O-sulphation of N-sulphated glucosamine (REFS 13, 40) . These modified sulphated domains are the principal binding sites for FGFs 40 . Notably, the modification of heparan sulphate by sulphation and epimerizatio n is regulated in a tissue-specific fashion, and hence different tissues can produce heparan sulphate chains with a distinct 'fine structure' 13, 40 , which influences FGF activity.
Heparan sulphate mediates the formation of paracrine FGF gradients in the extracellular matrix 36,41-43 , which determine cellular processes such as cell migration, cell proliferation and specification of cell fate during tissue morphogenesis and patterning in embryonic development. Recent studies on FGF7 subfamily ligands, which play essential parts in the branching morphogenesis of a number of glandular organs, have provided new insight into how these FGF gradients are formed and how the biological response to an FGF ligand is dictated by the shape of this gradient [43] [44] [45] . FGF10 has greater binding affinity for heparan sulphate than its subfamily member FGF7 (REF. 43) (FIG. 3a) . As a result, the diffusion of FGF10 in the extracellular matrix is more restricted than that of FGF7, and hence FGF10 forms a short, steep gradient close to its source, whereas FGF7 forms a long, shallow gradient spreading away from its source 43 (FIG. 3b) . In explants of developing submandibular gland tissue, FGF10 causes elongation of epithelial gland buds, whereas FGF7 induces bud branching 43 (FIG. 3c,d ). Reducing the heparan sulphate-binding affinity of FGF10 by replacing Arg187 in its heparan s ulphate-binding site with Val, which is the corresponding residue in FGF7, converts FGF10 functionally into an FGF7-like morphogen 43 (FIG. 3a-c) . By contrast, reducing the receptor-binding affinity of FGF10 affects the degree, but not the nature, of the morphogenetic activity of FGF10 (REF. 43 ). Thus, the differences in heparan sulphate-binding affinity between FGF7 and FGF10, which translate into differently shaped extracellular ligand gradients, alone account for the distinct morphogenetic activities of these ligands. Similarly, the aberrant activity of the FGF9 mutant carry ing a N143T mutation 42 , a spontaneous dominant mutation causing Elbow knee synostosis (Eks) in mice 46 , is due to altered heparan sulphate-binding affinity and hence altered gradient formation of the mutant FGF9 compared with wild-type ligand 42 . The cells that secrete FGF ligand also produce heparan sulphate, the 'fine structure' of which is crucial for mediating the formation of an FGF gradient in the extracellular matrix. In addition, the 'fine structure' of the heparan sulphate produced by the cells that are responding to FGF is crucial for ligand signalling. This is suggested by the findings that abrogation of glycosaminoglycan biosynthesis selectively in mesen chymal cells of the developing eye, which secrete FGF10, leads to excessive diffusion of FGF10 through the extracellular matrix and, as a consequence, a lack of FGF10-induced budding of the prospective lacrima l gland epithelium 45 . Moreover, the formation of the extracellular FGF10 gradient that results in induction of lacrimal gland budding requires heparan sulphate produced by the mesenchyme around the developing gland to be modified by N-sulphation but not 2-O-or 6-O-sulphation 45 . By contrast, FGF10 signalling to the epithelium of the developing gland requires heparan sulphate produced by the epithelium to be modified by 2-O-and 6-O-sulphation 44 . Thus, distinct modifications of heparan sulphate in the mesenchyme and epithelium may provide another layer of control for directional FGF signalling from the mesenchyme to the epithelium and vice versa (see below). In addition, distinct heparan sulphate modifications in different FGF-secreting cells, or in the same cell at different stages of embryonic development, may give rise to the formation of distinct gradients of specific FGF ligands, resulting in diverse biological responses.
Dimerization of FGF ligand. Unique among FGFs, ligands of the FGF9 subfamily undergo reversible homodimerization, which controls their biological activity 36, 38, 42 . The crystal structures of the homodimer s of FGF9 and FGF20 have illuminated the role of homodimerization as an autoinhibitory mechanism. In the structures, both the β-trefoil core and the N-terminal and C-terminal regions flanking the core participate in the dimer formation, with extensive interactions between the N-terminal and C-terminal regions of each monomer being the driving force 36,38 (FIG. 4a) . Notably, about half of the residues involved in ligand homo dimerization are also predicted to mediate receptor binding 36, 38 (FIG. 4b) . In other words, the ligand homodimer is incompatible with receptor binding, and hence the dimer must dissociate into monomers in order to enable ligand-receptor interactions. These structural findings suggest that homo dimerization autoinhibits the activity of FGF9 subfamily ligands by downregulating the effective concentration of ligand monomer that can bind and activate the receptor. Consistent with this mechanism, mutations that disrupt Nature Reviews | Molecular Cell Biology Heparan sulphate octasaccharide contacts in the dimer interface of FGF9 or FGF20 cause a shift in the ligand monomer to dimer equilibrium in solution towards the monomeric ligand form 36 . The mutated FGF9 and FGF20 ligands exhibit increased receptor binding and, as a consequence, increased biological activity compared with wild-type ligands 36 . Notably, the extent of increased receptor binding caused by a dimer interface mutation correlates with the degree of ligand monomerization that is caused 36 . In addition to downregulating the concentration of monomeric ligand that is available to interact with receptors, homodimerization autoinhibits ligand activity by restricting the signalling radius of the ligand.
The mutated FGF9 and FGF20 ligands, which have a reduced ability to homodimerize, also exhibit reduced binding affinity for heparan sulphate compared with wild-type ligands 36 . As a result, the mutated ligands diffuse over a greater distance in the extracellular matrix than their wild-type counterparts and hence have a greater signalling radius than them 36 . A recent study demonstrated the biological importance of homodimerization in the regulation of FGF9 activity 42 . This study identified an N143T mutation in FGF9 as the spontaneous mutation that causes a primarily skeletal phenotype in mice with Eks, a hallmark of which is the synostosis of elbow and knee joints 42, 46 (FIG. 4c) . Replacement of Asn143, which lies in the FGF9 dimer interface, with Thr weakens FGF9 homodimerization 42 . As a consequence, the N143T mutant exhibits reduced binding affinity for heparan sulphate, and hence diffuses over a greater distance in developing tissue than wild-type FGF9 (REF. 42) (FIG. 4d) . This hyperdiffusion leads to ectopic FGF9 signalling 42 , which underlies the Eks phenotype. These findings demonstrate that FGF ligand homodimerization enhances the binding affinity of ligand for heparan sulphate, thereby restricting ligand diffusion in the extracellular matrix and, as a consequence, limiting the signalling radius of the ligand. Taken together, ligand homodimerization autoinhibits the activity of FGF9 subfamily ligands at two levels: it inhibits ligand-receptor binding by occluding receptorbinding sites on the ligand, and it reduces the ability of the ligand to diffuse in the extracellular matrix by promoting ligand-heparan sulphate binding. . The dimer interface can be divided into two regions (black circles), one containing residues of the β-trefoil core domain and the other containing the amino-terminal and carboxy-terminal regions flanking the core domain. Extensive hydrophobic and hydrogen-bonding contacts between the N-terminal and C-terminal regions of the two monomers in the dimer drive homodimerization. Note that Asn143, which is spontaneously mutated in mice with Elbow knee synostosis (Eks), is located in the core region of the dimer interface. b | The molecular surface of an FGF9 monomer (dark yellow; PDB ID: 1IHK) 38 is shown with residues that exclusively mediate ligand dimerization depicted in light blue, and residues that mediate dimerization and are also predicted to bind FGF receptors shown in dark blue. Note that the bifunctional residues account for about half of the residues that form the ligand dimer interface (red boundary). c | Joint synostosis in developing limb tissue caused by the N143T mutation leading to Eks. Forelimbs of a newborn mouse with Eks and a newborn wild-type mouse are shown. The elbow joints (marked by arrows) are also shown at greater magnification. In the forelimb of the mouse with Eks, humerus (h) and radius (r) bones are fused together at the prospective elbow joint, and humerus and ulna (u) 
Idiopathic hypogonadotropic hypogonadism
Hereditary disorder characterized by the failure of sexual maturation and infertility due to deficiency of gonadotropin-releasing hormone.
Renal phosphate wasting disease
Inherited or acquired condition characterized by excessive renal excretion of phosphate due to impaired tubular reabsorption.
Hyperphosphatemia
Increase in blood phosphate levels above normal.
Alternative splicing of FGF ligand. Unlike other FGFs, the biological activity of ligands of the FGF8 subfamily is regulated by alternative splicing. The genes encoding FGF8 and FGF17, but not the FGF18 gene, are alternatively spliced to generate ligand isoforms with N termini of varying length and sequence [47] [48] [49] [50] . In humans, there are four isoforms of FGF8 (FGF8a, FGF8b, FGF8e and FGF8f) 48 and two isoforms of FGF17 (FGF17a and FGF17b) (FIG. 5a) . The importance of N-terminal splicing in regulating the biological activity of these ligands has been demonstrated by studies on the roles of FGF8a and FGF8b in midbrain and hindbrain patterning. Both splice isoforms are expressed by the isthmic organizer, which is a signalling centre within the anterior neural plate that directs the patterning of midbrain and anterior hindbrain (the cerebellum) 47, 51 . When ectopically expressed in the neural plate of chick embryos, FGF8a induces an expansion of midbrain tissue into the forebrain region, whereas FGF8b induces cerebellum formation in regions of prospective midbrain and caudal forebrain 51 (FIG. 5b) . Likewise, in mouse embryos, ectopic expression of FGF8a in the midbrain causes an overgrowth of midbrain tissue, whereas FGF8b transforms the midbrain into cerebellum 52, 53 . FGF8a and FGF8b also differ in their ability to induce mesoderm formation 54, 55 , and mutations at the spliced N-terminal region of FGF8 found in patients with idiopathic hypogonadotropi c hypogona dism impair the biological activity of the affected isoforms 56 . These findings illustrate the biological significance of N-terminal alternative splicing.
The crystal structure of FGF8b in complex with FGFR2c has unveiled the molecular mechanism by which N-terminal splicing regulates the biological activity of FGF8 (REF. 37) (FIG. 5c) . In the structure, hydrophobic residues from the N-terminal G helix and the β4-β5 loop of FGF8b bind to a hydrophobic groove in the D3 domain of FGFR2c 37 . Notably, among the FGF8b residues that interact with the receptor groove, a single residue, Phe32, is from the isoform-specific N-terminal sequence 37 . As FGF8a lacks this sequence, the numbe r of hydrophobic contacts is reduced in an FGF8a-recepto r complex as compared to an FGF8b-receptor complex, and hence FGF8a binds more weakly to receptors than FGF8b. Indeed, replacement of Phe32 with Ala in FGF8b reduces its receptor-binding affinity to a similar level to that of FGF8a
37
, and converts FGF8b functionally into an FGF8a-like ligand 37 (FIG. 5b) . Thus, N-terminal alternative splicing regulates ligand activity by modulating the binding affinity of ligand for receptor, and differences in receptor-binding affinity underlie the distinct biological activities of the FGF8 splice isoforms. It is likely that differences in receptor-binding affinity among the members of other ligand subfamilies also contribute to the distinct biological activities of those ligands.
Proteolytic cleavage of FGF ligand. Specific proteolytic processing of FGF ligands also regulates their activity. FGF23, which functions as a hormone that controls phosphate and vitamin D metabolism 30, 31 , is inactivated by proteolytic cleavage at the 176 Arg-Xaa-Xaa-Arg 179 motif (where Xaa represents any amino acid) that is located at the boundary between its β-trefoil core domain and its 72 amino acid long C-terminal tail 57,58 . The Arg-Xaa-Xaa-Arg motif is recognized by pro protein convertases that cleave specifically at basic amino acid residues and belong to the family of subtilisin-like Ser endoproteases 59 . These convertases cleave secretory proteins in subcellular organelles such as the Golgi complex, at the cell surface or in the extracellular matrix, and in most cases they convert a protein precursor into an active protein 59 . The cleavage occurs C-terminally to the second Arg residue of the Arg-Xaa-Xaa-Arg motif 59 , and can be inhibited by O-glycosylation of Ser or Thr residues within or adjacent to the cleavage site 60 . Although the endoprotease that cleaves FGF23 is unidentified, recent studies have provided insight into the mechanism by which proteolytic cleavage inactivates FGF23 (REF. 35 ). It was shown that FGF23 binds to preformed binary complexes of FGFR and α-Klotho co-receptor 35 . The ligand interacts with a de novo binding site that is generated at the composite receptorco-receptor interface in these binary complexes 35 . The region on FGF23 that binds to this de novo site was mapped to the 72 amino acid long C-terminal tail, which follows the β-trefoil core domain 35 . Thus, the N-terminal fragment of proteolytic cleavage (Tyr25 to Arg179, which includes the β-trefoil core domain) is metabolically inactive 57 because it lacks the binding site for the FGFR-α-Klotho complex. The C-terminal proteolytic fragment (Ser180 to Ile251), however, can compete with full-length FGF23 for binding to the FGFR-α-Klotho complex to antagonize the metabolic activity of FGF23, because this fragment contains the binding site for the FGFR-α-Klotho complex 35 . These findings suggest a dual mechanism by which proteolytic cleavage at the Arg-Xaa-Xaa-Arg motif in activates FGF23; the cleavage removes the binding site for the FGFR-α-Klotho complex from FGF23 and concomitantly generates an endogenous inhibitor of FGF23. Inhibition of this proteolytic cleavage by missense mutations within the Arg-Xaa-Xaa-Arg motif in FGF23 leads to accumulation of full-length, bioactive FGF23, causin g renal phosphate wasting disease in humans 57, 58, 61 . Conversely, enhanced FGF23 cleavage due to impaired O-glycosylation of FGF23 leads to a deficit in full-length FGF23, which manifests as hyperphosphatemia and soft tissue calcification in humans 62, 63 . Therefore, specific proteolytic processing of FGF23 is essential for regulating the activity of this hormone. It is currently not known whether FGF19 and FGF21, the other two members of the endocrine FGF subfamily, undergo proteolyti c proces sing in order to be inactivated.
Interestingly, ligands of the FGF7 subfamily contain an Arg-Xaa-Xaa-Arg cleavage motif in the N-terminal region preceding the β-trefoil core domain, and cultured mammalian cells secrete both full-length FGF7 ligand and the C-terminal fragment that results from proteolytic cleavage at the Arg-Xaa-Xaa-Arg motif 64 . However, whether specific proteolytic cleavage of FGF7 subfamily ligands occurs in vivo and is crucial for regulating the activity of these ligands is currently (FIG. 1b) . The ectodomain region encompassing D2, D3 and the D2-D3 linker is necessary and sufficient for ligand binding 2 (FIG. 1b,c) . Specificity of ligand binding by FGFR1, FGFR2 and FGFR3 is primarily determined by alternative splicing in the D3 domain of these receptors, which generates FGFRb and FGFRc isoforms 37, 39, [66] [67] [68] [69] [70] [71] [72] . This splicing event is fundamental to the establishment of directional FGF signalling between epithelial and mesenchymal tissues. FGF-FGFR binding induces FGFR dimerization 4 , which juxtaposes the intracellular kinase domains of the receptors so that one kinase can phosphorylate and hence activate the other 5, 6 . Subtle differences in receptor dimerization are induced by distinct ligands, and these may translate into differences in receptor activation that yield distinct biological responses.
Alternative splicing in the D3 domain of FGFR. Ligandbinding specificity of FGFR1, FGFR2 and FGFR3 is regulated by alternative splicing in the D3 domain of these receptors 37, 39, [66] [67] [68] [69] [70] [71] [72] . The N-terminal portion of the D3 domain is encoded by exon 7 (also known as exon IIIa), whereas the C-terminal portion is encoded by one of two mutually exclusive exons, exon 8 (also known as exon IIIb) or exon 9 (also known as exon IIIc) 66, 68, 69 . This alternative splicing is largely tissue-specific, with the expression of the FGFRb splice isoform generally being restricted to epithelial cell lineages and the expression of the FGFRc splice isoform by and large limited to mesenchymal cell lineages 69, 70, 73 . These receptor splice isoforms exhibit a distinct ligand-binding specificity profile 67, [69] [70] [71] [72] . The epithelial FGFRb isoforms specifically bind FGF ligands that are secreted from mesenchymal tissue and, conversely, the mesenchymal FGFRc isoforms preferentially interact with FGF ligands that are secreted from epithelial tissue 74 . This reciprocal expression of receptor splice isoforms and cognate ligands creates specific paracrine FGF signalling loops between the epithelium and the mesenchyme, which are crucial for orchestrating developmental processes and also for regulating tissue homeostasis in the adult [75] [76] [77] [78] [79] [80] [81] (FIG. 6a) . In the developing lung, for example, bidirectional FGF signalling between the epithelial layer and the surrounding mesenchyme underlies the coordination of mesen chymal proliferation and epithelial branching that governs normal lung organogenesis. Specifically, FGF9 secreted by the epithelium stimulates proliferation of the mesenchyme 76 , whereas FGF10 secreted by the mesenchyme acts on the epithelium to induce budding and branching 78, 79 . Notably, the reciprocal expression of receptor splice isoforms and cognate ligands not only establishes directional paracrine FGF signalling but safeguards against illegitimate autocrin e FGF signalling.
The crystal structures of ligand-bound FGFR2b and FGFR2c splice isoforms have provided molecular insight into how alternative splicing in the D3 domain controls ligand-binding specificity 37, 39, 82 (FIG. 6b-d) .
In the structure of FGF10 in complex with its cognate receptor, FGFR2b, FGF10 residues bind to a cleft in the D3 domain of FGFR2b 39 . One side of this cleft is formed by the FGFR2b splice isoform-specific βC'-βE loop. At the ligand-D3 domain cleft interface, unique hydrogen bonding contacts between Asp76 of FGF10 (a residue specific to FGF10 and other FGF7 sub family ligands) and Ser315 of FGFR2b (a residue specific for FGFR2b) are crucial in determining the binding specificity of FGFR2b towards FGF10 (REF. 39) (FIG. 6b,c) . The crucial role of the Asp76-Ser315 interaction for the ligand-binding specificity of FGFR2b is underscored by the finding that replacement of Ser315 in FGFR2b with Ala, the corresponding residue of FGFR2c, greatly reduces the ability of FGFR2b to bind FGF7 (REF. 83 ). FGF2, a member of the FGF1 subfamily, specifically binds to FGFR2c. The crystal structure of the FGF2-FGFR2c complex shows that, similar to the mode of FGF10 binding to the D3 domain of FGFR2b, FGF2 residues interact with the D3 domain cleft of FGFR2c, which is formed in part by the receptor isoform-specifi c βC'-βE loop 82 (FIG. 6d) . As is the case for FGF10-FGFR2b binding, unique hydrogen bonding contacts between FGF2 and the βC'-βE loop of FGFR2c determine binding specificity. These are the hydrogen bonds formed between Gln65 of FGF2, a residue unique to FGF2, and Asp321 of FGFR2c, an isoform-specific residue of the βC'-βE loop of the receptor (FIG. 6d) . Together, the structural data show that the alternative splicing in the D3 domain of FGFR2 confers ligand-binding specificity by changing the sequence of key ligand-binding residues or ligand-binding pockets.
Receptor mutations that disrupt ligand-binding specificity set by alternative splicing cause developmental skeletal disorders. The D321A mutation in FGFR2c, for example, causes Pfeiffer syndrome 84, 85 , an autosomal dominant disorder characterized by premature synostosi s of cranial sutures. The mutation greatly reduces the binding affinity of FGFR2c for FGF2 and, at the same time, enables FGFR2c to interact with the non-cognate ligand FGF10 86 . The loss in binding affinity of the mutant receptor for FGF2 can be explained by the loss of highly specific hydrogen bonding contacts between Asp321 in FGFR2c and Gln65 in FGF2 (REF. 82) (FIG. 6d) . The concomitant gain in the ability of the mutant receptor to bind FGF10 is likely due to the loss of steric clashes and electrostatic repulsion between Asp321 of FGFR2c and Asp76 of FGF10, which preclude binding of FGF10 to the wild-type receptor. By disrupting ligand-binding specificity, the D321A mutation enables autocrine FGF signallin g in the mesenchyme, and such illegitimate signalling in the developing cranial suture leads to craniosynostosis as seen in Pfeiffer syndrome. The effects of the mutation of key ligand-binding residues in the receptor, similarly to the D321A mutation in FGFR2c, underscore the central role of alternative splicin g in regulating the specificity of FGF signalling.
Ligand-induced dimerization of FGFR. Paracrine FGFs require heparan sulphate as a cofactor to robustly bind FGFR and promote the formation of a stable FGF-FGFR signal transducing complex at a ratio of 2:2 (REF . 4) (FIGS 1c,7a) . In the complex, each ligand interacts with both receptors, and the two receptors also interact directly with each other. These multi valent ligand-recepto r and recepto r-receptor contacts are fortified by heparan sulpha te, which simultaneously engages ligand and recept or in the complex. At the primary ligand-recepto r inter action site, an extensive network of hydroge n bonds is formed between the 39 is shown, along with a view of the whole structure. The ligand is coloured orange, the receptor D3 domain is coloured green (common N-terminal portion) and teal (alternatively spliced C-terminal portion). A network of hydrogen bonds (dashed lines) is formed between FGF10 and the isoform-specific βC'-βE loop of FGFR2b. Within this network, the hydrogen bonds between Asp76 of FGF10 (a residue unique to FGF10 and other FGF7 subfamily ligands) and Ser315 of FGFR2b (an isoform-specific residue of the βC'-βE loop) determine binding specificity. ligand, the receptor D2-D3 linker and the recepto r D3 domain 4, 37, 39, 82, [87] [88] [89] (FIG. 7b,c) . This hydrogen-bonding network confers structural rigidity on the interface between the ligand and the D3 domain and D2-D3 linker of the receptor, and its composition and geometry thus determine the orientation of the D3 domain and the D2-D3 linker in the receptor dimer. Comparative analysis of the crystal structures of FGF-FGFR complexes has identified three receptor residues and two ligand residues as key constituents of the hydro genbonding network (FIG. 7b) . The receptor residues, an Arg residue in the D2-D3 linker and an Asp and a Gln residue in the βB'-βC loop of the D3 domain, are conserved among mammalian FGFRs. The ligand residues, a Glu residue in the β8 strand and an Asp in the β9 strand, are nearly completely conserved among the mammalian FGFs. Importantly, these receptor and ligand residues also form entropically favourable intramolecular hydrogen bonds with similarly conserved residues. In ligand-receptor complexes containing this conserved core of hydrogen-bonding inter actions at the interface between the ligand and the D3 domain and D2-D3 linker of the receptor, the orientation of the D3 domain and D2-D3 linker is similar. Accordingly, the distance between the C-terminal membrane insertion points of the D3 domains in a dimer of ligand-bound receptors is similar among these complexes (FIG. 7a) . This is the case for complexes of FGFR with FGF1 subfamily ligands or FGF10 (REFS 4, 39, 82, (87) (88) (89) .
By contrast, two of the key residues in the hydrogenbonding network seen in these complexes are not conserved in FGF8 subfamily ligands, namely the Asp and a Tyr residue in the β9 strand. These substitutions, together with other divergent residues, account for an altered composition and geometry of the hydrogenbonding network in the FGF8b-FGFR2c complex, and hence for a different orientation of the D3 domain and D2-D3 linker in comparison to the other FGF-FGFR complexes 37 (FIG. 7c) . As a result of the different domain orientation, the C-terminal membrane insertion points of the D3 domains are closer to each other in a dimer of FGF8b-bound receptors than in the dimers of receptors bound to other FGF ligands 37 (FIG. 7a) . Such differences in the spatial positioning of the receptor ectodomains among different FGF-FGFR complexes may translate into differences in the juxtapositioning of the intracellular receptor kinase domains and distinct signalling outputs. In the case of an FGF8 signalling complex, the kinase domains would be closer to each other than in other FGF signalling complexes. This might generate the more intense or persistent signal that might be required for FGF8 functions such as the organizer activity at signallin g centres that drive brain and limb development.
Klotho co-receptors in FGF signalling
Endocrine FGFs depend on Klotho co-receptors for signalling because compared to paracrine FGFs, these ligands have intrinsically low binding affinity for both heparan sulphate and FGFR 14, 90 . Their low affinity for heparan sulphate enables these FGFs to signal in an endocrine fashion, whereas their low affinity for FGFR safeguards against nonspecific offtarget signalling. Klotho co-receptors, which include α-Klotho, β-Klotho and γ-Klotho, are members of the Klotho subfamily [91] [92] [93] [94] of family 1 β-glycosidases [95] [96] [97] . Klotho co-receptors contai n an extracellular domain composed of 1 (γ-Klotho) or 2 (α-Klotho and β-Klotho) β-glycosidase-like domains, a single-pass transmembrane domain and a short cytoplasmic tail [91] [92] [93] (FIG. 1b) . α-Klotho is required for FGF23 signalling 19, 20, 23 and β-Klotho is required for signalling by FGF19 and FGF21 (REFS 17, 18, 21, 22) . γ-Klotho may function as an additional co-receptor in FGF19 signalling 98 , but in vivo evidence for such a role is lacking. Expression of α-Klotho and β-Klotho co-receptors is restricted to the target tissues of endocrine FGFs 98 , where these coreceptors constitutively associate with cognate FGFRs of endocrine FGFs 18, 19, 21, 23 . When bound to α-Klotho or β-Klotho co-receptors, FGFRs exhibit high affinity for endocrine ligands 18, 19, 21, 23, 35, 90 . Although this role of α-Klotho and β-Klotho is fairly well established, recent findings have provided new insight into the mechanism by which these co-receptors convert FGFRs into specific receptors for endocrine FGFs 99 . Similarly to ligands of the FGF4, FGF8 and FGF9 subfamilies 2, 74 , α-Klotho and β-Klotho preferentially bind to the FGFRc splice isoforms of FGFR1, FGFR2 and FGFR3 (REFS 19, 21, 23, 99, 100) . This raised the possibility that the binding site for α-Klotho and β-Klotho co-receptors on FGFR may overlap with the binding site for these paracrine FGFs. Indeed, it was shown that α-Klotho and β-Klotho engage the conserved hydrophobic groove in the D3 domain of FGFRc isoforms 99 , which is also used by FGF8 subfamily ligands for receptor binding 37 (FIG. 5c) . Thus, the complex formation of α-Klotho and β-Klotho co-receptors with FGFRc isoforms and FGFR4, which also contains the hydrophobic groove in its D3 domain, obscures the binding site for FGF8 subfamily ligands and, as a result, inhibits signalling by these ligands 99 . This mechanism is likely to be biologically relevant, as α-Klotho and β-Klotho coreceptors and FGF8 subfamily ligands are co-expressed in several adult tissues, such as the liver, kidney and mature ovarian follicles 18, 23, [101] [102] [103] . Notably, α-Klotho and β-Klotho co-receptors are also co-expressed with other paracrine FGFs in adult tissues 25, 104 and might also inhibit signalling by these FGFs by binding to FGFRs at a site that overlaps with that of these ligands. Together, the findings support the concept of a dual mechanism by which α-Klotho and β-Klotho convert FGFRs into specific receptors for endocrine FGFs; these co-receptor s not only enhance the binding affinity of FGFRs for endocrine ligands but concomitantly suppress the binding of paracrine FGFs, such as FGF8 subfamily ligands, to FGFRs. In essence, Klotho co-receptors modify the ligand-binding specificity of FGFRs in favour of endocrine FGFs. This co-receptor function probably evolved to dedicate FGFRs in target cells of endocrine FGFs exclusively to endocrine FGFs, avoiding any interference from paracrine FGFs. Yet another role for Klotho co-receptors in endocrine FGF signalling is suggested by a recent study demonstrating that heparan sulphate is dispensable for the metabolic activity of endocrine FGFs 90 . This study showed that endocrine FGF mutants devoid of residual heparan sulphate binding have the same capacity as the native ligands to activate FGFR in the presence of α-Klotho or β-Klotho co-receptor and to elicit metabolic effects in vivo 90 . Thus, heparan sulphate is not a component of the endocrine FGF signal transduction unit (FIG. 1d) , which in turn implies that Klotho co-receptors fulfil the same role in the formation of the endocrine FGF signalling complex as heparan sulphate does in the formation of the paracrine FGF signalling complex. This suggests that Klotho co-receptors promote FGFR dimerization upon endocrine FGF bindin g, which is required for FGFR kinase activation. . The FGF2-FGFR2c model was created in a similar manner using FGF2 from the FGF2-FGFR2c structure (PDB ID: 1EV2) 82 . Note the differences in the orientation of the receptor D3 domain and D2-D3 linker between the two dimers of ligand-bound FGFR2c, which translate into differences in the spatial distance between the carboxy-terminal membrane insertion points of the D3 domains. b | The interface between the ligand and the D3 domain and D2-D3 linker of the receptor in the FGF2-FGFR2c structure (PDB ID: 1EV2) 82 is shown. The ligand is coloured orange, the receptor is coloured green (D2-D3 linker and common amino-terminal portion of the D3 domain) and teal (alternatively spliced C-terminal portion of the D3 domain). The network of hydrogen bonds (dashed lines) formed at this interface is highly conserved among complexes of FGFR with FGF1 subfamily ligands or FGF10. Its key constituents comprise Glu105 and Asn113 of FGF2 and Arg251, Asp283 and Gln285 of FGFR2c. Most of these residues also form entropically favourable intramolecular hydrogen bonds with similarly conserved residues, such as Glu105 and Asn113 of FGF2 with Tyr115 of FGF2. c | The interface between the ligand and the D3 domain and D2-D3 linker of the receptor in the FGF8b-FGFR2c structure (PDB ID: 2FDB) 37 is shown. Ligand and receptor are coloured as in part b. The composition and geometry of the network of hydrogen bonds (dashed lines) formed at this interface differ from that observed in the FGF2-FGFR2c complex (see, part b). For example, Asn113 and Tyr115 of FGF2 are replaced with Thr and Leu, respectively, in FGF8b. The side chain of Glu131 in FGF8b, the corresponding residue to Glu105 in FGF2, adopts a different rotamer conformation compared to that in the FGF2-FGFR2c complex as it makes an intramolecular hydrogen bond with Lys176, a residue specific to FGF8 subfamily ligands. A total of four hydrogen bonds unique to the FGF8b- 
Conclusion and perspective
Recent advances have improved our understanding of the structural basis of FGF signalling and provided a glimpse at the complexity of molecular control that is in place for this essential signalling system. Importantly, the structural findings suggest that there may be no functional redundancy among FGF ligands. This is supported by genetic studies that demonstrate that the gene knockout of one FGF ligand cannot be compensated for by any other member of the same FGF subfamily. For example, FGF10-deficient mouse embryos show agenesis of the lungs 78, 79 , aplasia of the salivary glands 105 and hypoplasia of the mammary glands 106 , whereas mouse embryos lacking FGF7 exhibit defects in ureteric bud growth and branching in the developing kidney 107 . The distinct phenotypes caused by these gene knockouts reflect that, although FGF7 and FGF10 are closely related members of the same subfamily and both branching morphogens, these ligands cannot substitute for one another. Perhaps even more strikingly, FGF7 and its subfamily member FGF22 both promote the differentiation of presynaptic terminals on dendrites of CA3 pyramidal neurons in the hippocampus 108 . However, the two ligands promote the formation of functionally distinct synapses 108 , and neither ligand can replace the other. Hence, future studies should be directed at identifying novel ligand-specific functions of FGF signalling.
Although it is established that Klotho co-receptors convert FGFRs into specific receptors for endocrine FGFs, a full understanding of the molecular basis for this functional conversion awaits the determination of the crystal structure of a ternary complex of endocrine FGF with FGFR and Klotho co-receptor. A ternary complex structure may also unveil how Klotho co-receptors promote FGFR dimerization upon endocrine FGF binding and provide clues as to why an endocrine FGF signallin g complex sends a weaker signal than a paracrine FGF signalling complex 18, 23 . Importantly, this crystal structure would also offer a template for the structure-based design of endocrine FGF agonists or antagonists for the treatment of metabolic disorders.
Moreover, although it is known that paracrine FGFs cooperate with one another to direct developmental processes, it has yet to be explored how paracrine FGF signalling is integrated with endocrine FGF signalling to regulate metabolism. The latest discoveries on the roles of FGF1 and FGF21 in the dynamic remodelling and metabolic activity of adipose tissue may set the stage for future investigations in this direction. Both FGF1 and FGF21 are induced postprandially in gonadal white adipose tissue by the nuclear hormone receptor PPARγ (peroxisome proliferator activated receptor-γ) 26,109 , which is a major regulator of adipocyte differentiation and metabolic function 110 . FGF1 is required for the remodelling of adipose tissue to adjust to fluctuations in nutrient availability 26 , and this process is influenced by FGF21 (REFS 109,111) . Notably, as part of a positive feedback loop, FGF21 stimulates PPARγ activity in adipocytes 109 , raising the intriguing possibility that FGF21 regulates FGF1 signalling in adipose tissue through PPARγ. Nuclear hormone receptor signalling might therefore serve as a mechanism that integrates the functions of endocrine FGFs and paracrine FGFs in the contro l of metabolic homeostasis.
Lastly, key questions remain in regard to the molecular basis of FGF signal transduction specificity. For example, what determines the speed, extent and duration of transphosphorylation of FGFR kinases in a ligand-bound FGFR dimer? Moreover, how do the speed, extent and duration of kinase transphosphorylation contribute to the generation of distinct signalling outputs? Future studies addressing these questions and more are poised to unravel new layers of molecular control, which operate to fine-tune FGF signalling. Answering these questions may not only advance our understanding of how FGFs generate specific signalling outputs in enormously diverse biological contexts but also pave the way for new treatments for disorders caused by dysregulated FGF signalling.
